Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial for the development of KH-001 as first FDA-approved treatment for premature ejaculation

Kanna Health Ltd Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom United States of America England

View original content:https://www.prnewswire.co.uk/news-releases/kanna-health-announces-fda-and-mhra-approvals-to-begin-its-phase-1-clinical-trial-for-the-development-of-kh-001-as-first-fda-approved-treatment-for-premature-ejaculation-301987937.html